Drugs / MAGE-A3
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00257738 | Nov 2005 → Oct 2012 | head and neck squamous cell carcinoma | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00090493 | Jun 2004 → Jul 2007 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01437605 Comparator | Oct 2011 → Jul 2018 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-03-16 | Gilead Sciences | Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR) gilead.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-A3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00090493 ↗ |
| Modality | Vaccine | “MAGE-A3/HPV 16 Vaccine” NCT00257738 ↗ |
| Route | Subcutaneous | “Administered Subcutaneously” NCT00257738 ↗ |